These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37836576)

  • 21. [Construction of a nomogram prediction model for pathological complete response (pCR) of ipsilateral supraclavicular lymph node after neoadjuvant chemotherapy for breast cancer with first diagnosis of ipsilateral supraclavicular lymph node metastasis].
    Lyu MH; Jiao DC; Wu JZ; Tian PQ; Ma YZ; Liu ZZ; Chen XC
    Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):160-166. PubMed ID: 35184460
    [No Abstract]   [Full Text] [Related]  

  • 22. A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer.
    Tan W; Luo W; Jia W; Liang G; Xie X; Zheng W; Song E; Su F; Gong C
    Oncotarget; 2016 Dec; 7(52):87312-87322. PubMed ID: 27894097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
    Pang J; Wang S; Liao L; Liu X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and validation of a new prognostic immune-inflammatory-nutritional score for predicting outcomes after curative resection for intrahepatic cholangiocarcinoma: A multicenter study.
    Zhu J; Wang D; Liu C; Huang R; Gao F; Feng X; Lan T; Li H; Wu H
    Front Immunol; 2023; 14():1165510. PubMed ID: 37063918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and Validation of a Preoperative Magnetic Resonance Imaging Radiomics-Based Signature to Predict Axillary Lymph Node Metastasis and Disease-Free Survival in Patients With Early-Stage Breast Cancer.
    Yu Y; Tan Y; Xie C; Hu Q; Ouyang J; Chen Y; Gu Y; Li A; Lu N; He Z; Yang Y; Chen K; Ma J; Li C; Ma M; Li X; Zhang R; Zhong H; Ou Q; Zhang Y; He Y; Li G; Wu Z; Su F; Song E; Yao H
    JAMA Netw Open; 2020 Dec; 3(12):e2028086. PubMed ID: 33289845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and Validation of an MRI-Based Nomogram Model for Predicting Disease-Free Survival in Locally Advanced Rectal Cancer Treated With Neoadjuvant Radiotherapy.
    Chen S; Tang Y; Li N; Jiang J; Jiang L; Chen B; Fang H; Qi S; Hao J; Lu N; Wang S; Song Y; Liu Y; Li Y; Jin J
    Front Oncol; 2021; 11():784156. PubMed ID: 34869040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and validation of a prognostic nomogram based on the log odds of positive lymph nodes (LODDS) for breast cancer.
    Wen J; Ye F; He X; Li S; Huang X; Xiao X; Xie X
    Oncotarget; 2016 Apr; 7(15):21046-53. PubMed ID: 26992235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study.
    Kim SH; Jung KH; Kim TY; Im SA; Choi IS; Chae YS; Baek SK; Kang SY; Park S; Park IH; Lee KS; Choi YJ; Lee S; Sohn JH; Park YH; Im YH; Ahn JH; Kim SB; Kim JH
    Cancer Res Treat; 2016 Oct; 48(4):1373-1381. PubMed ID: 27034147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nomogram for predicting axillary lymph node pathological response in node-positive breast cancer patients after neoadjuvant chemotherapy.
    Wang W; Wang X; Liu J; Zhu Q; Wang X; Wang P
    Chin Med J (Engl); 2021 Dec; 135(3):333-340. PubMed ID: 35108228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
    Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
    Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Establishment of a prognostic nomogram to predict long-term survival in non-metastatic colorectal cancer patients].
    Wang X; Chi P; Lin H; Lu X; Huang Y; Xu Z; Huang S; Sun Y; Ye D
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jun; 20(6):654-659. PubMed ID: 28643310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Inflammatory and Nutritional Prognostic Scoring System for Nonpathological Complete Response Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.
    Jiang C; Xiu Y; Zhang S; Yu X; Qiao K; Huang Y
    Dis Markers; 2022; 2022():8044550. PubMed ID: 36569222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of CRP-albumin-lymphocyte index (CALLY index) as a prognostic biomarker in patients with non-small cell lung cancer.
    Liu XY; Zhang X; Zhang Q; Ruan GT; Liu T; Xie HL; Ge YZ; Song MM; Deng L; Shi HP
    Support Care Cancer; 2023 Aug; 31(9):533. PubMed ID: 37610445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors Affecting Pathologic Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer: Development and Validation of a Predictive Nomogram.
    Kim SY; Cho N; Choi Y; Lee SH; Ha SM; Kim ES; Chang JM; Moon WK
    Radiology; 2021 May; 299(2):290-300. PubMed ID: 33754824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of Preoperative Radiomics Signature on the Survival of Breast Cancer Patients With Residual Tumors After NAC.
    Zhang L; Jiang X; Xie X; Wu Y; Zheng S; Tian W; Xie X; Li L
    Front Oncol; 2020; 10():523327. PubMed ID: 33614472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development, verification, and comparison of a risk stratification model integrating residual cancer burden to predict individual prognosis in early-stage breast cancer treated with neoadjuvant therapy.
    Hou N; Wu J; Xiao J; Wang Z; Song Z; Ke Z; Wang R; Wei M; Xu M; Wei J; Qian X; Xu X; Yi J; Wang T; Zhang J; Li N; Fan J; Hou G; Wang Y; Wang Z; Ling R
    ESMO Open; 2021 Oct; 6(5):100269. PubMed ID: 34537675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nottingham Clinico-Pathological Response Index (NPRI) after neoadjuvant chemotherapy (Neo-ACT) accurately predicts clinical outcome in locally advanced breast cancer.
    Abdel-Fatah TM; Ball G; Lee AH; Pinder S; MacMilan RD; Cornford E; Moseley PM; Silverman R; Price J; Latham B; Palmer D; Chan A; Ellis IO; Chan SY
    Clin Cancer Res; 2015 Mar; 21(5):1052-62. PubMed ID: 25520390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
    Qiao W; Guo W; Liu Q; Guo X; Deng M
    Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk Stratification Using Neoadjuvant Rectal Score in the Era of Neoadjuvant Chemoradiotherapy: Validation With Long-term Outcome Data.
    Lim YJ; Song C; Jeon SH; Kim K; Chie EK
    Dis Colon Rectum; 2021 Jan; 64(1):60-70. PubMed ID: 33306532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.